Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Feb 18 | 2022ICER Report Questions Tirzepatide’s Effectiveness Compared to Ozempic and Jardiance; Signos and Dexcom to Launch CGM+AI-Enhanced App Trial; Teladoc Launches Chronic Care Complete Program; Movano Completes Second Glucose Pilot Study; Better Therapeutic Enrolls First Patient in BT-001 RWE StudyPurchase Blast
$599
Posted in: Insulin Delivery, Other Feb 17 | 2022Insulet Partners with Nintendo’s Animal Crossing Game; Beta Bionics Raises $57M in Series C FinancingPurchase Blast
$599
Posted in: Bolus Insulin, Insulin Delivery, Other Feb 16 | 2022Tandem’s Mobile Bolus Feature Cleared by FDAPurchase Blast
$599
Posted in: Other, SGLT2i Feb 15 | 2022Novo Sues Teva Over Generic Saxenda; Cytokinetics Announces Disappointing METEORIC-HF Results; Zealand’s Pediatric Ph3 Dasiglucagon in CHI Trial Completes EnrollmentPurchase Blast
$599
Posted in: Glucose Monitoring, Other Feb 14 | 2022Nemaura CY Q4 ‘21 and FY ’21 (FY Q3 ‘22) Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring, Other Feb 11 | 2022Will AZ Fund an Additional Roxa Trial?; Senseonics Eversense E3 CGM Receives FDA ApprovalPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Feb 10 | 2022Dexcom Q4 ‘21 and FY ‘21 Earnings UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Feb 10 | 2022AZ Q4 '21 and FY '21 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Other Feb 09 | 2022Did Lilly Purchase BioMarin's PRV?; Rivus Announces Positive Ph2a HU6 Trial Results; Second Sight to Merge with Nano Precision for GLP-1RA ImplantablePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Feb 08 | 2022Amgen Business Review Meeting and FY ’21 Earnings; Pfizer Q4 ’21 EarningsPurchase Blast
$599
Posted in: Glucose Monitoring, Other Feb 07 | 2022Diamyd to Initiate Ph3 DIAGNODE-3 Trial in Europe; First Patient Dosed with CRISPR and ViaCyte's VCTX210 in Ph1 Trial; Know Labs Bio-RFID Device Receives IRB ApprovalPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Insulin Delivery, SGLT2i Feb 04 | 2022Novo Q4 '21 London Earnings; Sanofi and Regeneron Q4 ‘21 and FY ‘21 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Other, SGLT2i Feb 03 | 2022Lannett, Merck, Roche, and BD Q4 ‘21 and FY ’21 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Other, SGLT2i Feb 03 | 2022Lilly Q4 ‘21 and FY ‘21 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Feb 02 | 2022Novo Q4 and FY ’21 Earnings UpdatePurchase Blast
$599
Posted in: Other Jan 31 | 2022Pfizer and Ionis Discontinue Vupanorsen in Dyslipidemia; Glooko Acquires xbird; Madrigal Announces Positive Ph3 MAESTRO-NAFLD-1 Topline ResultsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 28 | 2022Insulet Omnipod 5 Receives FDA Clearance; BI/Lilly’s Jardiance HFpEF Indication Receives Positive CHMP Opinion; Provention Hosts Teplizumab BLA Resubmission Call with Investors; Lilly to Invest $1.5B in Two New Manufacturing SitesPurchase Blast
$599
Posted in: GLP-1RA, Other Jan 27 | 2022Provention Bio to Resubmit Teplizumab BLA; Novo’s Wegovy Shortage Resolution Appears on Track; Vertex Q4 ’21 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Jan 26 | 2022Libre 3 Filed as iCGM in US; Abbott Q4 '21 Earnings Update; FDA Warns Lilly for Misleading Trulicity Instagram PromoPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
